New biologic drug CM518D1 enters human trials for advanced cancers
NCT ID NCT07019779
First seen Nov 17, 2025 · Last updated Jun 23, 2026 · Updated 28 times
Summary
This study tests an experimental drug called CM518D1 in people with advanced solid tumors that have not responded to standard treatments. The trial has two phases: first to find a safe dose, then to see if the drug can shrink tumors. About 434 participants will receive the drug intravenously every three weeks.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMORS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Sun Yat-sen University Cancer Center (SYSUCC)
RECRUITINGGuangzhou, Guangdong, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
CM518D1 (an experimental biologic drug given intravenously)
What this could lead to
If successful, this could point toward a new treatment option for people with advanced solid tumors that have not responded to other therapies.
What could go wrong
This is an early-phase trial (Phase 1/2) focused on safety and dosing, so it is not yet proven to work. Side effects are possible, and the drug may not shrink tumors or improve survival.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.